A research team led by King’s College London has unveiled a chemical redesign strategy that keeps antibiotics working inside bacterial cells, even against drug-resistant strains. The approach could breathe new life into existing antibiotics that bacteria have already learned to overcome.
Researchers have developed a novel antibiotic design framework that could change how scientists tackle one of medicine’s most urgent challenges: drug-resistant bacterial infections. The study, led by King’s College London and published in the Journal of Medicinal Chemistry, introduces a strategy called “Efflux Resistance Breaker,” or ERB, which rewires the chemical structure of antibiotics so bacteria can no longer expel them before they work.
How Bacteria Dodge Antibiotics — and How ERB Fights Back
One of the most common ways bacteria develop resistance is through molecular pumps embedded in their cell walls, known as efflux pumps. These pumps act like bouncers, ejecting antibiotic molecules before the drug can accumulate to a lethal concentration inside the cell. The result is a bacterium that survives treatment it should not be able to withstand.
The ERB method tackles this by chemically restructuring antibiotic molecules themselves, making them harder for efflux pumps to recognize and remove. Once inside a bacterial cell, the redesigned antibiotic lingers at higher concentrations — long enough to do its job and kill the bacteria.
Senior author Khondaker Miraz Rahman, a professor of medicinal chemistry at King’s College London, emphasized both the urgency and the promise of this work:
“Antimicrobial resistance is rising, but the number of truly new antibiotics in development remains worryingly low. Our work shows that we can redesign antibiotics so they stay inside bacterial cells at higher concentrations and overcome resistance mechanisms that would normally make them ineffective,” Rahman said in a news release. “This approach could help us design better new antibiotics, but it could also help revive existing antibiotic classes that bacteria have learned to defeat.”
A Built-In Defense, Not a Patch
What separates the ERB approach from earlier strategies is that resistance-breaking capability is woven directly into the antibiotic molecule itself — not added as a separate companion drug. Previous efforts often paired antibiotics with standalone efflux pump inhibitors, a two-drug combination that introduces its own set of complications. With ERB, the antibiotic is essentially designed to protect itself from ejection.
Co-author J. Mark Sutton of the UK Health Security Agency, a key collaborator on the project, described the significance of the chemical design approach:
“Efflux pumps are a major cause of antibiotic resistance because they reduce the concentration of drug inside the bacterial cell. This study shows that rational chemical design can be used to overcome that problem. By building efflux resistance directly into the antibiotic, we may be able to restore activity against bacteria that are no longer controlled by current drugs,” Sutton said in the news release.
The study serves as a proof of concept, demonstrating that sustaining high concentrations of antibiotic within bacterial cells can overcome resistance — including in strains that have already developed reduced sensitivity to current medications.
Why It Matters for Students and Young Adults
Antimicrobial resistance is not a distant or abstract problem. College campuses, dormitories, gyms and clinics are environments where bacterial infections spread easily — and where drug-resistant strains like MRSA have long posed real threats to students. As more bacteria evolve defenses against the antibiotics doctors rely on, infections that were once straightforward to treat can become dangerous or even life-threatening.
The World Health Organization has flagged antimicrobial resistance as one of the top global public health threats, estimating that drug-resistant infections already cause hundreds of thousands of deaths each year. Without new or revitalized treatments, that toll is expected to rise sharply in coming decades — making breakthroughs like ERB especially significant for the generation that will live with those consequences.
What Comes Next
The team is now working to commercialize the ERB platform and move antibiotics developed under this framework toward clinical trials. The goal is to translate the laboratory findings into treatments patients can actually use against drug-resistant infections.
Beyond developing new drugs, the researchers believe ERB could serve as a broad strategy for reviving older antibiotic classes that have lost their edge — potentially expanding the arsenal available to doctors without requiring the full cost and timeline of discovering an entirely new drug class from scratch.
Source: King’s College London